[Other] Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study

Hystrix65 Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-06-30 17:29
Reward20points

journalㄩMinerva Urology and Nephrology

AuthorsㄩPasquale RESCIGNO; Tarek TAHA; Maria J. FITA; Diana MATTHEWS; Kazutoshi FUJITA; Cristian LOLLI; Fabrizio DI COSTANZO; Alvaro JUREZ; Y邦ksel RN; Sati C. YAZGAN; Haoran LI; Gaetano FACCHINI; Mar赤a N. QUIROGA; Enrico SAMMARCO; Martin BGEMANN; Daniele SANTINI; Jalal BARANSEH; Giandomenico ROVIELLO; Ray M. KOPP; Ondej FIALA; Thomas BTTNER; Francesco CARROZZA; Jawaher ANSARI; Deniz TURAL; Vincenza CONTEDUCA; Javier MOLINA-CERRILLO; Teresa ALONSO-GORDOA; Maria T. BOURLON; Georgia A. PALACIOS; Federico PAOLIERI; Anca ZGURA; Roberta DI ROCCO; Leonardo G. LACERENZA; Marc R. MATRANA; Angelo MARTIGNETTI; Francesco MASSARI; Andrey SOARES; Fernando S. MONTEIRO; Diogo A. BASTOS; Luke GAUGHAN; Mike WENZEL; Philipp MANDEL; Giuseppe L. BANNA; Matteo SANTONI

Published dateㄩ--

DOIㄩ10.23736/s2724-6051.26.06453-0

PDF linkㄩhttps://www.minervamedica.it/pdf.php?cod=R19Y9999N00A26062301

Article linkㄩhttps://doi.org/10.23736/s2724-6051.26.06453-0

Article SourceㄩEdizioni Minerva Medica


Remarkㄩ
Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Return to the list